Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1750912 | 1.00 | TSHR (0.31) | TSHR | |
| SCHEMBL17050838 | 1.00 | TSHR (0.31) | TSHR | |
| SCHEMBL8076557 | 0.86 | — | — | |
| SCHEMBL20528062 | 0.81 | — | — | |
| SCHEMBL19285106 | 0.81 | — | — | |
| SCHEMBL20522832 | 0.81 | — | — | |
| SCHEMBL19285784 | 0.81 | — | — | |
| SCHEMBL6598570 | 0.80 | — | — | |
| SCHEMBL6598575 | 0.80 | — | — | |
| SCHEMBL16317827 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117917416-A | KRAS G12D degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-117917410-A | Pan-KRAS degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-04-23 | — | — | CN | disclosed |
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
| CN-113943296-A | Pyrrolopyrimidine derivatives and uses thereof | 武汉人福创新药物研发中心有限公司 | 2022-01-18 | — | — | CN | disclosed |
| EP-1939191-A1 | Furan derivatives, method of synthesis and uses thereof | Neuropharma S.A. (ES) | 2008-07-02 | — | — | EP | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5580872-A | ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| WO-1995010519-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1995-04-20 | — | — | WO | disclosed |
| US-4892961-A | Amino acid derivatives, and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-01-09 | — | — | US | disclosed |
| EP-0210657-B1 | AMINO ACID DERIVATIVES, AND THEIR PRODUCTION | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1989-05-03 | — | — | EP | disclosed |
| EP-0210657-A1 | Amino acid derivatives, and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | TSHR 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.